Evidence map›Paper›PMID 32594420›Full record

ArticleJournal of thrombosis and thrombolysis2021

Role of prothrombin 19911 A>G polymorphism, blood group and male gender in patients with venous thromboembolism: Results of a German cohort study.

Verena Limperger, Gili Kenet, Bettina Kiesau, Max Köther, Malin Schmeiser, Florian Langer, David Juhl, Maria Shneyder, Andre Franke, Ulrich K Klostermeier and 12 more

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. International journal of molecular sciences · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 5 countries.

Verena Limperger *UKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany. verena.limperger@gmail.com.ORCID http://orcid.org/0000-0003-4138-0161
Gili Kenet *National Hemophilia Center, Institute of Thrombosis and Hemostasis, Sheba Medical Centre, Tel-Hashomer, Israel.
Bettina KiesauUKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany.
Max KötherUKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany.
Malin SchmeiserUKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany.
Florian LangerDepartment of Hematology & Oncology, Univ. Hospital Hamburg, Hamburg, Germany.
David JuhlInstitute of Transfusion Medicine, Univ. Hospital Kiel & Lübeck, Lübeck, Germany.
Maria ShneyderUKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany.
Andre FrankeInstitute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.
Ulrich K KlostermeierUKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany.
Rolf MestersDepartment of Medicine/ Hematology & Oncology, Univ. Hospital Münster, Münster, Germany.
Frank RühleInstitute of Human Genetics, Westfälische-Wilhelms-University, Münster, Germany.
Monika StollInstitute of Human Genetics, Westfälische-Wilhelms-University, Münster, Germany.
Dagmar SteppatInstitute of Transfusion Medicine, Univ. Hospital Kiel & Lübeck, Lübeck, Germany.
Dorothee KowalskiUKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany.
Angela RockeUKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany.
Piotr KutaUKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany.
Tido BajoratUKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany.
Antje TorgeUKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany.
Bruno NeunerDepartment of Anesthesiology and Intensive Care Medicine, Charité - Universitätsmedizin Berlin, Campus Charité Mitte and Campus Virchow-Klinikum, Berlin, Germany.
Ralf Junker *UKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany.
Ulrike Nowak-GöttlUKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany. leagottl@uksh.de.
University of Lübeck · DEUniversity of Münster · DECharité - Universitätsmedizin Berlin · DEChristian-Albrechts-Universität zu Kiel · DEGEOMAR Helmholtz Centre for Ocean Research Kiel · DEHess (United States) · USSheba Medical Center · ILUniversity Hospital Münster · DE

Funding

Gesellschaft für Thrombose und Hämostaseforschung/ Society of Thrombosis and Hemostasis Research" (GTH) GTH 2016Interdisziplinäres Zentrum für Klinische Forschung IZKF: CRA01-09
6 · The paper itself

Abstract

The role of the A>G polymorphism at position 19911 in the prothrombin gene (factor [F] 2 at rs3136516) as a risk factor for venous thromboembolism [VTE] is still unclear. To evaluate the presence of the F2 polymorphism in VTE patients compared to healthy blood donors and to adjust the results for common inherited thrombophilias [IT], age at onset and blood group [BG], and to calculate the risk of VTE recurrence. We investigated 1012 Caucasian patients with a diagnosis of VTE for the presence of the F2 rs3136516 polymorphism and compared these with 902 healthy blood donors. Odds ratios [OR] together with their 95% confidence intervals were calculated adjusted for F5 at rs6025, F2 at rs1799963, blood group, age and gender. In addition, we evaluated the risk of recurrent VTE during patient follow-up calculating hazard ratios [HR] together with their 95% CI. Compared with the AA wildtype, the F2 GG and AG genotypes (rs3136516) were associated with VTE (OR 1.48 and 1.45). The OR in F5 carriers compared to controls was 5.68 and 2.38 in patients with F2 (rs1799963). BG "non-O" was significantly more often diagnosed in patients compared to BG "O" (OR 2.74). VTE recurrence more often occurred in males (HR 2.3) and in carriers with combined thrombophilia (HR 2.11). Noteworthy, the rs3136516 polymorphism alone was not associated significantly with recurrence. In Caucasian patients with VTE the F2 GG/GA genotypes (rs3136516) were moderate risk factors for VTE. Recurrence was associated with male gender and combined thrombophilia.

Indexed as

Blood Group AntigensPolymorphism, Single NucleotideAdultFemaleGenetic Predisposition to DiseaseGermanyHumansMaleMiddle AgedProthrombinRisk FactorsSex FactorsVenous ThromboembolismYoung AdultBlood Group AntigensProthrombinMale genderProthrombin 19911 A>G polymorphismRecurrenceThrombosis

Identifiers

PMID32594420
PMCPMC7886710
OpenAlexW3038025903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.